迪戈辛的处方. 迪戈辛的处方. 主要是好消息
JAMA
|August 3, 1979
概括
医生根据患者的年龄,脏疾病和心房动调整了狄戈辛剂量,这表明了良好的处方实践. 然而,不到40%的处方偏好了品牌名字迪戈辛 (Lanoxin),尽管人们担心通用生物可用性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 家庭医学 家庭医学 家庭医学
背景情况:
- 迪戈辛是治疗心脏病,如心房动的关键药物.
- 与创新品牌Lanoxin相比,仿制迪戈辛配方的生物可用性和治疗等价性仍然存在担忧.
- 优化迪戈辛的处方实践对于患者的安全和治疗疗效至关重要.
研究的目的:
- 为了评估一个大型家庭医疗实践中的迪戈辛处方模式.
- 根据患者因素,评估遵守推剂量调整的情况.
- 为了确定用于品牌产品 (Lanoxin) 和仿制药的迪戈辛处方的比例.
主要方法:
- 从家庭医疗实践中对47000份处方进行了回顾性分析.
- 鉴定了254名接受511张迪戈辛处方的患者.
- 检查与年龄,病和心房动状态有关的剂量调整.
主要成果:
- 在16%的64岁以上患者和33%的病患者中观察到剂量减少.
- 在心房的患者中,剂量增加了39%,符合临床指南.
- 不到40%的迪戈辛处方是针对创新品牌 (Lanoxin) 的,尽管存在生物可用性问题.
结论:
- 迪戈辛的处方证明了对关键患者人口统计和疾病进行适当的剂量调整.
- 品牌Lanoxin的利用率很低,因此需要进一步调查,特别是关于仿制狄戈辛的生物可用性.
- 确保最佳的狄戈辛治疗需要持续关注配方选择和患者特定的剂量.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Dysrhythmias VII: Nursing Management of Dysrhythmias
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
Cardiomyopathy VI: Nursing Management
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...


